POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

FDA OKs COVID-19 booster shot for people 65 and older, or at high risk

Christian Fernsby |
The U.S. Food and Drug Administration (FDA) on Wednesday authorized booster shots of Pfizer's COVID-19 vaccine for people aged 65 and older or at high risk.

Article continues below




"After considering the totality of the available scientific evidence and the deliberations of our advisory committee of independent, external experts, the FDA amended the EUA (emergency use authorization) for the Pfizer-BioNTech COVID-19 Vaccine to allow for a booster dose in certain populations such as health care workers, teachers and day care staff, grocery workers and those in homeless shelters or prisons, among others," said Acting FDA Commissioner Janet Woodcock.

"This pandemic is dynamic and evolving, with new data about vaccine safety and effectiveness becoming available every day. As we learn more about the safety and effectiveness of COVID-19 vaccines, including the use of a booster dose, we will continue to evaluate the rapidly changing science and keep the public informed," said Woodcock.

The FDA said boosters are authorized for people between the ages of 18 through 64 who are at high risk, as well as those "whose frequent institutional or occupational exposure" to the virus puts them at high risk of serious complications of COVID-19.

The agency said booster doses are to be administered at least six months after completion of the second shot.


What to read next

FDA panel rejects call for third Pfizer booster shot
Dramatic increase in e-cigarette use among youth in U.S.
FDA continues to ensure safety and effectiveness of authorized COVID-19 vaccines